[NTDTV 2009-9-2 11:40]
China`s food and drug administration say clinical trials of a vaccine against the H1N1 flu strain have been successful.
Drug maker Sinovac Biotech is the world`s first to complete the trials in the battle against the bug more commonly known as swine flu.
The National Vaccine and Serum Institute says the shot will protect a wide age range.
[Zhao Kai, National Vaccine and Serum Institute]:
“15 micrograms of the vaccine has been temporarily approved for use on people between the ages of three to 60 against flu caused by the H1N1 virus.”
Swine flu is hitting younger people especially hard, unlike the seasonal kind which the elderly are more likely to suffer.
Different countries have different ideas about who should be vaccinated.
The completion of clinical trials puts Sinovac Biotech a step nearer to mass producing such a vaccine – and that`s been showing in its share price.